18 Recruiting Studies Using Ivosidenib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Ivosidenib
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
📍 Washington University School of Medicine — St Louis, Missouri
Clonal Cytopenia of Undetermined Significance
View Study & Checklist ➔An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
📍 Erebouni MC — Yerevan,
Cholangiocarcinoma
View Study & Checklist ➔Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Recurrent Ependymoma
View Study & Checklist ➔Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
📍 University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
📍 Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Acute Myeloid Leukemia
View Study & Checklist ➔IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
📍 University of Colorado — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
📍 Emory University — Atlanta, Georgia
IDH1-Mutated Malignancies
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
📍 Presbyterian / St. Luke'S Medical Center — Denver, Colorado
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
View Study & Checklist ➔Ivosidenib as Post-HSCT Maintenance for AML
📍 Emory University Hospital — Atlanta, Georgia
IDH1 Mutation
View Study & Checklist ➔CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia With Gene Mutations
View Study & Checklist ➔Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Myeloproliferative Neoplasms
View Study & Checklist ➔A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
📍 Cancer and Blood Speciality Clinic - Los Alamitos — Los Alamitos, California
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
View Study & Checklist ➔Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
📍 Usc Norris Comprehensive Cancer Center — Los Angeles, California
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
View Study & Checklist ➔Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔